NetworkNewsBreaks – Pivot Pharmaceuticals Inc. (
Post# of 52
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) this morning issued a corporate update detailing its recent activity. Per the release, the company has had a “very active” start to the current calendar year, with its management team working to build a “differentiated” company in the cannabis sector by focusing on improving the cannabis consumer experience with scientifically-derived products. Pivot’s notable corporate highlights include its proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner. “I am extremely proud of the entire Pivot team as we continue to execute our business plan,” Dr. Patrick Frankham, CEO of Pivot, stated in the news release. “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes. We continue to believe that sustainable cannabis companies will have pipelines of products to meet the needs of consumers seeking wellness and healthy lifestyles.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer